Web23 uur geleden · Price To Cash Flow is a widely used stock evaluation measure. ... Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates 02/28/23-10:25AM EST Zacks. Web13 apr. 2024 · Allspring Global Investments Holdings LLC lifted its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) by 890.6% during the …
FDA-Approved Medicines Kiniksa Pharmaceuticals
Web13 apr. 2024 · Allspring Global Investments Holdings LLC lifted its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Rating) by 890.6% during the 4th quarter, according to its most recent disclosure with the SEC.The fund owned 215,119 shares of the company's stock after purchasing an additional 193,404 shares during the … Web5 apr. 2024 · The latest price target for Kiniksa Pharmaceuticals ( NASDAQ: KNSA) was reported by JP Morgan on Thursday, March 9, 2024. The analyst firm set a price target for 20.00 expecting KNSA to rise to... dacc register
Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Price, News, Quote
Web30 mrt. 2024 · Kiniksa Pharmaceuticals Stock Price Today (NASDAQ: KNSA) Quote, Market Cap, Chart WallStreetZen Kiniksa Pharmaceuticals Ltd Stock Add to … Web13 jan. 2024 · The market capitalization of Kiniksa Pharmaceuticals is $686 522 000. At the same time, the number of shares in circulation is 34 275 000. The company's earnings before interest, taxes and depreciation for last year (called EBITDA) was -127 973 000$. The company has no profit and is unprofitable. WebKiniksa Pharmaceuticals, Ltd. (KNSA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. dacc registrar